Answers are grounded in this paper and cite their sources.
Systematic review examines acne incidence in inflammatory bowel disease, indicating increased risk with JAK inhibitors.
Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.
No takes yet. Share an insight, caveat, or question.
Quraishi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: